Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib With BR/CR for Untreated Mantle Cell Lymphoma
NCT03623373Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2018
- Primary completion
- Feb 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), sponsored by Washington University School of Medicine. Primary endpoint: Stem Cell Mobilization Success Rate With Cytarabine and Rituximab. Started Nov 2018; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03623373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623373.